Albany, New York (09/25/2014) – Insist Therapeutics Inc (NASDAQ:INSY) is named as the Arizona Bioscience Company of 2014. The award has been given by the Arizona Bioindustry Association. It is given for an innovative product development and accelerating growth in the industry. Insys belongs to the list of companies who had the most amazing IPO in 2013. The company has provided with more than 380% growth in shareholder value. Now it had a market cap exceeding $800 million last year. Joan Koerber-Walker, the CEO of AZBio, said that investors have benefited, and now it is the turn of patients to benefit from the innovative products.
OHR Pharmaceutical Inc (NASDAQ:OHRP) and many other biotech stocks are posting good gains. Some of them are posting gains on acquisitions news, some of them are getting the much awaited FDA approval for their drugs in the collective pipelines and while some of them are confident of their future prospects. OHR is also on the radar of buyers. The technical chart of OHR is not encouraging but still Brean Capital raised the price target of OHR’s stocks to $34.
Levi & Korsinsky on September 9 said that a class action lawsuit has been filed in the U.S. District Court on behalf of investors who bought China XD Plastics Company Ltd. (NASDAQ:CXDC) shares between August 12, 2009 and July 10, 2014. The complaint stated that China XD overstated its net income and revenue in the quarterly as well as annual reports issued to the U.S. investors.
Analysts at Jefferies Group have set a “buy” rating on Immunomedics, Inc. (NASDAQ:IMMU)’s stocks. They have a price target of $6.00 on the stock. Immunomedics reported its fourth-quarter results last month. It revenues came at $1.2 million comparable to $1.4 million in the 4Q2103. The revenues declined to the decline in R&D development revenue resulting from reduced grant activity.